The United States and India are launching separate regulatory initiatives to accelerate their respective drug approval and clinical trial processes. On September 15, 2026, the U.S. Food and Drug Administration opened applications for a pilot program under Operation TrialBlazer to speed up early-stage human trials and compete with biotech sectors in China and Australia. Meanwhile, India is proposing to ease rules for bioavailability and bioequivalence studies and halve import licensing timelines from 90 to 45 days.
India BA/BE study simplification
- ▪The Indian government proposed to allow drug approval applicants to start eligible bioavailability and bioequivalence studies for domestic drug approvals after intimating the drug regulator rather than requiring prior permission.
- ▪The proposed prior intimation system for bioavailability and bioequivalence studies in India excludes high-risk categories such as sex hormones, cytotoxic drugs, beta-lactam antibiotics, vaccines, cell and gene therapy products, biologics, and narcotics.
- ▪The Indian government's proposal to simplify bioavailability and bioequivalence study regulations was placed for deliberation before the Drugs Technical Advisory Board in September 2026.
India drug import timeline
- ▪The Indian government proposed to reduce the processing timeline for import licence applications under Form CT-17 for new drugs and reference products from 90 working days to 45 working days.
- ▪The Indian health ministry directed the drug regulatory authority to examine Rules 67, 68, 69, and 70 of the New Drugs and Clinical Trials Rules 2019 to improve the ease of doing business.
FDA human trial pilot
- ▪The United States Food and Drug Administration opened applications on September 15, 2026, for a pilot program designed to shorten the time it takes for drugmakers to begin testing products in humans.
- ▪The United States Food and Drug Administration's pilot program aims to assist pharmaceutical companies in transitioning more rapidly to testing their drug products in human clinical trials.
Operation TrialBlazer initiative
- ▪The United States Food and Drug Administration's human trial pilot program was first announced in June 2026 as part of Operation TrialBlazer, a Department of Health and Human Services clinical trials reform initiative.
- ▪The United States Department of Health and Human Services' Operation TrialBlazer initiative pledged to shorten the Food and Drug Administration's drug approval timelines.
US-China biotech competition
- ▪The United States Department of Health and Human Services noted in its TrialBlazer roadmap that the United States drug approval pathway often takes years, compared to other countries where pathways are measured in months.
- ▪The United States Department of Health and Human Services designed Operation TrialBlazer to help the United States compete with rapidly accelerating biotechnology industries in countries like China and Australia.
Debatable claims
- ▪India should permit drug trials to start without prior regulatory approval
- ▪The FDA should accelerate its clinical trial approval process
Story comments
Loading comments…